Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir
We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome. An experimental array-based assay (immun...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2014-01, Vol.19 (3), p.259-267 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 267 |
|---|---|
| container_issue | 3 |
| container_start_page | 259 |
| container_title | Antiviral therapy |
| container_volume | 19 |
| creator | DE NIET, Annikki JANSEN, Louis ZAAIJER, Hans L KLAUSE, Ursula TAKKENBERG, Bart JANSSEN, Harry L. A CHU, Tom PETRIC, Rosemary REESINK, Hendrik W |
| description | We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome.
An experimental array-based assay (immunological multi-parameter chip technology [IMPACT]; Roche Diagnostics, Penzberg, Germany) served to determine HBsAg, anti-HBs and complex levels. We tested a panel of serum samples of 40 hepatitis B e antigen (HBeAg)-positive and 44 HBeAg-negative patients who received pegylated interferon and adefovir for 48 weeks.
HBsAg loss occurred in 4 of 40 HBeAg-positive and 4 of 44 HBeAg-negative patients. A total of 14 of 40 HBeAg-positive patients lost HBeAg and 12 of them formed anti-HBe. At BL, complexes were present in 83 (99%) patients, whereas free anti-HBs levels were detectable in 5 patients. Complex levels at BL and week 12 were higher in HBeAg-positive patients with HBeAg loss, compared to patients who retained HBeAg (P=0.002 and P=0.005, respectively). Receiver operating characteristic analysis for HBeAg loss in HBeAg-positive patients at BL and week 12 showed area-under-the-curve values of 0.79 (P=0.002) and 0.82 (P=0.003) for complex levels. We found no correlation in either HBeAg-positive or -negative patients between complex levels and HBsAg loss.
We demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in HBeAg-positive CHB patients treated with pegylated interferon and adefovir. Complexes were present in almost all patients at BL and were higher in patients who lost HBeAg. In conclusion, determining HBsAg/anti-HBs immune complex levels before and early during treatment could aid in selecting CHB patients with an optimal chance to achieve HBeAg loss. |
| doi_str_mv | 10.3851/IMP2707 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1635020576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1635020576</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-15fe558f1360ff0a57c744070edf59df5e32d8b789000d8c02ca1d9d2e28c3773</originalsourceid><addsrcrecordid>eNqFkc1OGzEUha2KqqRQ9Q0qb6p2M8Vjj39mmSBakEB0UdYjY18nrib21HYoeRDetw4EumRh-Vj6fHTvOQh9bMk3pnh7cnH1k0oi36AZJR1pKOHqAM1axvtGcMYP0fucfxNCVU_IO3RIO8qFoGKGHs7uJ0h-DaHoEZ8v8nx5okPxTZXYxPU0wj3WOestdjHhKYH1pvgYcHQVh_kSjzFn7AM2qxSDN3gFky6--IwXeKeqdcYlgS5g8V9fVniC5XZ8fPpQIDmoH7EOFmsLLt75dIzeOj1m-LC_j9DN97Nfp-fN5fWPi9P5ZWNY15Wm5Q44V65lgjhHNJdGdh2RBKzjfT3AqFW3crc1scoQanRre0uBKsOkZEfo65PvlOKfDeQyrH02MI46QNzkoRWMkxqmFK-jvFOCUdrvXL88oSbVaBK4YaoJ67QdWjLs6hr2dVXy0950c7sG-8I991OBz3tAZ6NHl3QwPv_nlKjjScX-AaghnXE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1548632297</pqid></control><display><type>article</type><title>Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>DE NIET, Annikki ; JANSEN, Louis ; ZAAIJER, Hans L ; KLAUSE, Ursula ; TAKKENBERG, Bart ; JANSSEN, Harry L. A ; CHU, Tom ; PETRIC, Rosemary ; REESINK, Hendrik W</creator><creatorcontrib>DE NIET, Annikki ; JANSEN, Louis ; ZAAIJER, Hans L ; KLAUSE, Ursula ; TAKKENBERG, Bart ; JANSSEN, Harry L. A ; CHU, Tom ; PETRIC, Rosemary ; REESINK, Hendrik W</creatorcontrib><description>We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome.
An experimental array-based assay (immunological multi-parameter chip technology [IMPACT]; Roche Diagnostics, Penzberg, Germany) served to determine HBsAg, anti-HBs and complex levels. We tested a panel of serum samples of 40 hepatitis B e antigen (HBeAg)-positive and 44 HBeAg-negative patients who received pegylated interferon and adefovir for 48 weeks.
HBsAg loss occurred in 4 of 40 HBeAg-positive and 4 of 44 HBeAg-negative patients. A total of 14 of 40 HBeAg-positive patients lost HBeAg and 12 of them formed anti-HBe. At BL, complexes were present in 83 (99%) patients, whereas free anti-HBs levels were detectable in 5 patients. Complex levels at BL and week 12 were higher in HBeAg-positive patients with HBeAg loss, compared to patients who retained HBeAg (P=0.002 and P=0.005, respectively). Receiver operating characteristic analysis for HBeAg loss in HBeAg-positive patients at BL and week 12 showed area-under-the-curve values of 0.79 (P=0.002) and 0.82 (P=0.003) for complex levels. We found no correlation in either HBeAg-positive or -negative patients between complex levels and HBsAg loss.
We demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in HBeAg-positive CHB patients treated with pegylated interferon and adefovir. Complexes were present in almost all patients at BL and were higher in patients who lost HBeAg. In conclusion, determining HBsAg/anti-HBs immune complex levels before and early during treatment could aid in selecting CHB patients with an optimal chance to achieve HBeAg loss.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP2707</identifier><identifier>PMID: 24256626</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Adenine - analogs & derivatives ; Adenine - therapeutic use ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antigen-Antibody Complex - blood ; Antiviral agents ; Antiviral Agents - therapeutic use ; Area Under Curve ; Biological and medical sciences ; DNA, Viral - blood ; Female ; Hepatitis B Antibodies - blood ; Hepatitis B e Antigens - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus ; Hepatitis B virus - drug effects ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Hepatitis B, Chronic - virology ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Organophosphonates - therapeutic use ; Pharmacology. Drug treatments ; Polyethylene Glycols - therapeutic use ; Predictive Value of Tests ; Protein Array Analysis ; Protein Binding ; Recombinant Proteins - therapeutic use ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>Antiviral therapy, 2014-01, Vol.19 (3), p.259-267</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-15fe558f1360ff0a57c744070edf59df5e32d8b789000d8c02ca1d9d2e28c3773</citedby><cites>FETCH-LOGICAL-c344t-15fe558f1360ff0a57c744070edf59df5e32d8b789000d8c02ca1d9d2e28c3773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28602078$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24256626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DE NIET, Annikki</creatorcontrib><creatorcontrib>JANSEN, Louis</creatorcontrib><creatorcontrib>ZAAIJER, Hans L</creatorcontrib><creatorcontrib>KLAUSE, Ursula</creatorcontrib><creatorcontrib>TAKKENBERG, Bart</creatorcontrib><creatorcontrib>JANSSEN, Harry L. A</creatorcontrib><creatorcontrib>CHU, Tom</creatorcontrib><creatorcontrib>PETRIC, Rosemary</creatorcontrib><creatorcontrib>REESINK, Hendrik W</creatorcontrib><title>Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome.
An experimental array-based assay (immunological multi-parameter chip technology [IMPACT]; Roche Diagnostics, Penzberg, Germany) served to determine HBsAg, anti-HBs and complex levels. We tested a panel of serum samples of 40 hepatitis B e antigen (HBeAg)-positive and 44 HBeAg-negative patients who received pegylated interferon and adefovir for 48 weeks.
HBsAg loss occurred in 4 of 40 HBeAg-positive and 4 of 44 HBeAg-negative patients. A total of 14 of 40 HBeAg-positive patients lost HBeAg and 12 of them formed anti-HBe. At BL, complexes were present in 83 (99%) patients, whereas free anti-HBs levels were detectable in 5 patients. Complex levels at BL and week 12 were higher in HBeAg-positive patients with HBeAg loss, compared to patients who retained HBeAg (P=0.002 and P=0.005, respectively). Receiver operating characteristic analysis for HBeAg loss in HBeAg-positive patients at BL and week 12 showed area-under-the-curve values of 0.79 (P=0.002) and 0.82 (P=0.003) for complex levels. We found no correlation in either HBeAg-positive or -negative patients between complex levels and HBsAg loss.
We demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in HBeAg-positive CHB patients treated with pegylated interferon and adefovir. Complexes were present in almost all patients at BL and were higher in patients who lost HBeAg. In conclusion, determining HBsAg/anti-HBs immune complex levels before and early during treatment could aid in selecting CHB patients with an optimal chance to achieve HBeAg loss.</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - therapeutic use</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antigen-Antibody Complex - blood</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - immunology</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Organophosphonates - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Protein Array Analysis</subject><subject>Protein Binding</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1OGzEUha2KqqRQ9Q0qb6p2M8Vjj39mmSBakEB0UdYjY18nrib21HYoeRDetw4EumRh-Vj6fHTvOQh9bMk3pnh7cnH1k0oi36AZJR1pKOHqAM1axvtGcMYP0fucfxNCVU_IO3RIO8qFoGKGHs7uJ0h-DaHoEZ8v8nx5okPxTZXYxPU0wj3WOestdjHhKYH1pvgYcHQVh_kSjzFn7AM2qxSDN3gFky6--IwXeKeqdcYlgS5g8V9fVniC5XZ8fPpQIDmoH7EOFmsLLt75dIzeOj1m-LC_j9DN97Nfp-fN5fWPi9P5ZWNY15Wm5Q44V65lgjhHNJdGdh2RBKzjfT3AqFW3crc1scoQanRre0uBKsOkZEfo65PvlOKfDeQyrH02MI46QNzkoRWMkxqmFK-jvFOCUdrvXL88oSbVaBK4YaoJ67QdWjLs6hr2dVXy0950c7sG-8I991OBz3tAZ6NHl3QwPv_nlKjjScX-AaghnXE</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>DE NIET, Annikki</creator><creator>JANSEN, Louis</creator><creator>ZAAIJER, Hans L</creator><creator>KLAUSE, Ursula</creator><creator>TAKKENBERG, Bart</creator><creator>JANSSEN, Harry L. A</creator><creator>CHU, Tom</creator><creator>PETRIC, Rosemary</creator><creator>REESINK, Hendrik W</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20140101</creationdate><title>Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir</title><author>DE NIET, Annikki ; JANSEN, Louis ; ZAAIJER, Hans L ; KLAUSE, Ursula ; TAKKENBERG, Bart ; JANSSEN, Harry L. A ; CHU, Tom ; PETRIC, Rosemary ; REESINK, Hendrik W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-15fe558f1360ff0a57c744070edf59df5e32d8b789000d8c02ca1d9d2e28c3773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - therapeutic use</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antigen-Antibody Complex - blood</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - immunology</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Organophosphonates - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Protein Array Analysis</topic><topic>Protein Binding</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DE NIET, Annikki</creatorcontrib><creatorcontrib>JANSEN, Louis</creatorcontrib><creatorcontrib>ZAAIJER, Hans L</creatorcontrib><creatorcontrib>KLAUSE, Ursula</creatorcontrib><creatorcontrib>TAKKENBERG, Bart</creatorcontrib><creatorcontrib>JANSSEN, Harry L. A</creatorcontrib><creatorcontrib>CHU, Tom</creatorcontrib><creatorcontrib>PETRIC, Rosemary</creatorcontrib><creatorcontrib>REESINK, Hendrik W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DE NIET, Annikki</au><au>JANSEN, Louis</au><au>ZAAIJER, Hans L</au><au>KLAUSE, Ursula</au><au>TAKKENBERG, Bart</au><au>JANSSEN, Harry L. A</au><au>CHU, Tom</au><au>PETRIC, Rosemary</au><au>REESINK, Hendrik W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>19</volume><issue>3</issue><spage>259</spage><epage>267</epage><pages>259-267</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome.
An experimental array-based assay (immunological multi-parameter chip technology [IMPACT]; Roche Diagnostics, Penzberg, Germany) served to determine HBsAg, anti-HBs and complex levels. We tested a panel of serum samples of 40 hepatitis B e antigen (HBeAg)-positive and 44 HBeAg-negative patients who received pegylated interferon and adefovir for 48 weeks.
HBsAg loss occurred in 4 of 40 HBeAg-positive and 4 of 44 HBeAg-negative patients. A total of 14 of 40 HBeAg-positive patients lost HBeAg and 12 of them formed anti-HBe. At BL, complexes were present in 83 (99%) patients, whereas free anti-HBs levels were detectable in 5 patients. Complex levels at BL and week 12 were higher in HBeAg-positive patients with HBeAg loss, compared to patients who retained HBeAg (P=0.002 and P=0.005, respectively). Receiver operating characteristic analysis for HBeAg loss in HBeAg-positive patients at BL and week 12 showed area-under-the-curve values of 0.79 (P=0.002) and 0.82 (P=0.003) for complex levels. We found no correlation in either HBeAg-positive or -negative patients between complex levels and HBsAg loss.
We demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in HBeAg-positive CHB patients treated with pegylated interferon and adefovir. Complexes were present in almost all patients at BL and were higher in patients who lost HBeAg. In conclusion, determining HBsAg/anti-HBs immune complex levels before and early during treatment could aid in selecting CHB patients with an optimal chance to achieve HBeAg loss.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>24256626</pmid><doi>10.3851/IMP2707</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2014-01, Vol.19 (3), p.259-267 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1635020576 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenine - analogs & derivatives Adenine - therapeutic use Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antigen-Antibody Complex - blood Antiviral agents Antiviral Agents - therapeutic use Area Under Curve Biological and medical sciences DNA, Viral - blood Female Hepatitis B Antibodies - blood Hepatitis B e Antigens - blood Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B virus - drug effects Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Organophosphonates - therapeutic use Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Predictive Value of Tests Protein Array Analysis Protein Binding Recombinant Proteins - therapeutic use Treatment Outcome Viral diseases Viral hepatitis |
| title | Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A04%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experimental%20HBsAg/anti-HBs%20complex%20assay%20for%20prediction%20of%20HBeAg%20loss%20in%20chronic%20hepatitis%20B%20patients%20treated%20with%20pegylated%20interferon%20and%20adefovir&rft.jtitle=Antiviral%20therapy&rft.au=DE%20NIET,%20Annikki&rft.date=2014-01-01&rft.volume=19&rft.issue=3&rft.spage=259&rft.epage=267&rft.pages=259-267&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP2707&rft_dat=%3Cproquest_cross%3E1635020576%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1548632297&rft_id=info:pmid/24256626&rfr_iscdi=true |